{
    "nctId": "NCT03821454",
    "briefTitle": "Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant Chemotherapy",
    "officialTitle": "A Randomized, Double-blind, Placebo-controlled Study of Capecitabine in the Treatment of Early-stage Breast Cancer With Low-hormone Receptor Expression and Residual Invasive Carcinoma After Neoadjuvant Chemotherapy",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Event Free Survival(DFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Provision of informed consent\n2. Women and men at least 18 years of age or older.\n3. Pathological confirmation of breast cancer\n4. Tumor stage(TNM): T1-4N0-3M0\n5. No evidence of distant metastasis\n6. Adequate bone marrow, hepatic, and renal function\n7. Measurable disease as per RECIST criteria\n8. Karnofsky\u226570\n9. Laboratory criteria:\n\nPLT\u2265100\\*109/L WBC\u22654000/mm3 HGB\u226510g/dl ALT and AST\\<2\\*ULN\n\nExclusion Criteria:\n\n1. Presence of metastatic disease.\n2. Inflammatory breast cancer.\n3. Bilateral breast cancer.\n4. Postoperative treatment with other adjuvant chemotherapy drugs.\n5. Other malignant tumors (concurrent or previous).\n6. Pregnant woman.\n7. Hypersensitive to any drug in Capecitabine or any ingredient of Capecitabine.\n8. Any severe systemic disease contraindicating chemotherapy.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}